Valitor Appoints Ophthalmic and Biotech Veteran Gregory D. Kunst as CEO

Berkeley, CA, October 17, 2025 (Valitor Press Release) -- Valitor, a biotech company developing next-generation ophthalmic medicines, named Gregory D. Kunst as its new chief executive officer and board member. Kunst brings extensive experience across ophthalmic drugs, medical devices, cell and gene therapies, and biotech commercialization, succeeding interim CEO Michael Ostrach.

Kunst will lead Valitor’s advancement of VLTR-559, a long-acting anti-VEGF therapy for wet AMD, and drive clinical and commercial development leveraging the company’s multivalent biopolymer platform.

Prior to Valitor, Kunst founded and led Aurion Biotech, later sold to Alcon, and held senior leadership roles at Glaukos Corporation and Alcon/Novartis, launching multiple ophthalmology products and advancing clinical candidates.

Read full article here.